1. Inicio
  2. Proyectos y Estudios
  3. ENSAYO FASE 2, ABIERTO, MULTICÉNTRICO PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE DARATUNUMAB EN SUJETOS CON MIELOMA MÚLTIPLE QUE HAYAN RECIBIDO AL MENOS 3 LÍNEAS PREVIAS DE TRATAMIENTO (INCLUYENDO INHIBIDORES DEL PROTEOSOMA E INMUNOMODULADORES) O QUE SEAN DOBLE REFRACTARIOS A INHIBIDORES DEL PROTEOSOMA Y A INMUNOMODULADORES.

ENSAYO FASE 2, ABIERTO, MULTICÉNTRICO PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE DARATUNUMAB EN SUJETOS CON MIELOMA MÚLTIPLE QUE HAYAN RECIBIDO AL MENOS 3 LÍNEAS PREVIAS DE TRATAMIENTO (INCLUYENDO INHIBIDORES DEL PROTEOSOMA E INMUNOMODULADORES) O QUE SEAN DOBLE REFRACTARIOS A INHIBIDORES DEL PROTEOSOMA Y A INMUNOMODULADORES.

Datos básicos

Código:
54767414MMY2002(GEN505)
Protocolo:
54767414MMY2002(GEN505)
EUDRACT:
2013-000752-18
NCT:
Centro:
Dotación:
Año de incio:
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

JANSSEN CILAG INTERNATIONAL NV

Resultados del Ensayo Clínico

[Farewell open letter to SEFH members].

Poveda Andrés JL

Editorial Material. 10.7399/fh.2015.39.6.10128. 2015


[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence

Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda

Editorial Material. 10.1016/j.farma.2024.08.009. 2024

  • Open Access.

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024


[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024


[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

  • Open Access.

2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021


A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)

Vallejo C; (...); Codesido ML

Article. 10.1007/s00277-023-05602-x. 2024


A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022


A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022


A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Paiva B; (...); Grupo Español de MM

Article. 10.1038/leu.2013.166. 2013


A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.

de Andrés-Nogales F; (...); Martínez-Olmos J

Article. 10.1007/s41669-020-00201-2. 2020


A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

Casado, MA; (...); Grp MULTIDEX-EMD

Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018


A new definition and refocus of pharmaceutical care: the Barbate Document

Morillo-Verdugo R; (...); Poveda-Andrés JL

Article. 10.7399/fh.11389. 2020


A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco

Article. 10.1080/10428194.2021.1971216. 2021


A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Encinas, Cristina; (...); Martinez-Lopez, Joaquin

Article. 10.1038/s41408-022-00652-2. 2022


A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Article. 10.1038/tpj.2015.80. 2016


Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.

Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose

Article. 10.1002/cam4.5424. 2022


Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review

Romero, S; (...); Sanz, J

Review. 10.1177/20406207211038181. 2021


Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Ballesta-López O; (...); Poveda-Andrés JL

Article. 10.1177/1078155220915953. 2020


Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice

Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators

Article. 10.1080/21645515.2021.1953346. 2021


Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?

Guerreiro M; (...); Piñana JL

Article. 10.1111/tid.13602. 2021


Aflibercept in exudative age related macular degeneration refractory to ranibizumab.

Ruiz Ramos J; (...); Gallego-Pinazo R

Article. 10.1016/j.oftal.2015.07.018. 2015


Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study

De la Rubia, J; (...); Gonzalez, MS

Meeting Abstract. 2019


Analisis de las causas de suspension de tratamiento con triple terapia antiviral en pacientes con hepatitis C.

Ruiz Ramos J; (...); Poveda Andrés JL

Abstract of Published Item. 10.7399/fh.2014.38.3.1171. 2014


Analysing criteria for price and reimbursement of orphan drugs in Spain.

Badia, X; (...); Tort, M

Article. 10.7399/fh.11147. 2019


Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES

Cejalvo, MJ; (...); De la Rubia, J

Meeting Abstract. 2017

  • Open Access.

Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype

Ibanez, M; (...); Cervera, J

Article. 10.1038/s41598-020-61589-9. 2020


ANALYSIS OF THE CLINICAL EVOLUTION OF PATIENTS WHO UNDERWENT A SECOND AUTOTRANSPLANTATION OF PERIPHERAL BLOOD FOR RELAPSED MULTIPLE MYELOMA

Garcia, Ruiz Raquel; (...); Arnao, Herraiz Mario

Meeting Abstract. 2020

  • Open Access.

ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.

Cejalvo, MJ; (...); De la Rubia J

Meeting Abstract. 2018

  • Open Access.

Anidulafungin-Induced Alopecia

Ruiz-Ramos J; (...); Poveda-Andrés JL

Article. 10.1177/1060028014524534. 2014


Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018


Antimicrobial stewardship programme in critical care medicine: A prospective interventional study

Ruiz, J; (...); Catellanos, A

Article. 10.1016/j.medin.2017.07.002. 2018


Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023


Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.

de la Asunción CS; (...); Navarro D

Article. 10.1002/jmv.28933. 2023


Assessment of the quality of sample labelling for clinical research.

Pérez-Huertas P; (...); Poveda-Andrés JL

Article. 10.7399/fh.2016.40.2.9753. 2016


Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation

Sánchez-Lázaro I; (...); Aliño SF

Article. 10.2217/pgs.15.39. 2015


Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience

Sanz J; (...); Sanz GF

Article. 10.1038/bmt.2014.107. 2014


Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.

García-Sancho AM; (...); Caballero D

Article. 10.3324/haematol.2021.279426. 2022


Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).

Pascual-Izquierdo C; (...); Mingot-Castellano ME

Article. 10.1002/ajh.27498. 2024


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021


Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2018.12.027. 2019


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022


Biosimilares: viejas polemicas con nuevos argumentos.

Poveda-Andrés JL, Bosó-Ribelles V

Editorial Material. 10.7399/fh.2015.39.3.8978. 2015


BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017


Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017


Calidad y Legibilidad de la Hoja de Informacion al Paciente en Estudios con Analisis Farmacogenetico.

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 2015


Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.

Muntañola A; (...); Bosch F

Letter. 10.1186/s40164-020-00195-x. 2020


Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre

Arnao, M; (...); Sanz, G

Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019


Clinical evaluation of rituximab treatment for neuromyelitis optica

Fernández-Megía MJ; (...); Poveda-Andrés JL

Article. 10.1016/j.nrl.2014.09.001. 2015


Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Lorente Fernández L; (...); Casanova-Estruch B

Article. 10.1016/j.nrl.2013.06.014. 2014


Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019


Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Ibanez, Mariam; (...); Cervera, Jose

Meeting Abstract. 10.1182/blood.V128.22.598.598. 2016


CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.

Chorão P; (...); Sanz J

Article. 10.1016/j.jtct.2024.01.082. 2024


Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".

de la Rubia J

Article. 10.5581/1516-8484.20140020. 2014


COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA

Valenzuela, AV; (...); Ramos, IJ

Meeting Abstract. 2018

  • Open Access.

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Megias-Vericat, JE; (...); Poveda, JL

Meeting Abstract. 2020


Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation

Solves, P; (...); Sanz, GF

Article. 10.1111/ejh.13270. 2019


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts

Arenillas, Leonor; (...); Florensa, Lourdes

Meeting Abstract. 2016


Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category

Calvo, Xavier; (...); Florensa, Lourdes

Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016


Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome

Villalba, A; (...); Senent, L

Letter. 10.1007/s00277-018-3334-5. 2018


COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

  • Open Access.

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024


Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017


Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020


COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018


Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice

Lorente-Fernandez, L; (...); Poveda-Andres, JL

Article. 10.1136/ejhpharm-2013-000426. 2015


COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021


Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Puig N; (...); García-Sanz R

Article. 10.1038/leu.2013.217. 2014


Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1111/hae.13733. 2019


Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019


Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024


Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.

Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina

Article. 10.1093/mmy/myac038. 2022


Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.

Solano de la Asuncion, Carlos; (...); Navarro, David

Letter. 10.1111/bjh.17732. 2021


Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion

Lara, SH; (...); Suarez-Varela, MM

Article. 10.1007/s00408-018-0186-7. 2019


Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.

Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose

Article. 10.1016/j.gastrohep.2023.05.010. 2023


Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019


Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)

Lozano, Maria L.; (...); Vicente, Vicente

Article. 10.1038/s41598-021-95732-x. 2021


Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018


Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.

Mansilla-Polo M; (...); Botella-Estrada R

Letter. 10.1111/ddg.15502. 2024


Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE

Jarque, Ramos, I; (...); Shepherd, Moreno J.

Meeting Abstract. 2020

  • Open Access.

Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019


DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019


Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024


Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024


DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019


Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019


Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.

Pérez Huertas P; (...); Poveda Andrés JL

Article. 10.7399/fh.2015.39.4.8839. 2015


Drug Interaction Between Oral Cyclosporine Modified and Iron

Domingo-Chiva, E; (...); Poveda-Andres, JL

Article. 10.1177/1060028013514734. 2014


Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Megias-Vericat, JE; (...); Poveda, JL

Review. 10.1007/s10072-017-2833-9. 2017


ECONOMIC IMPACT LINKED TO THE REDUCTION OF EXACERBATIONS WHEN A TREATMENT REGIME WITH INHALED ANTIBIOTICS IS SWITCHED TO AZTREONAM LYSINE IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC PULMONARY INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA

Sole A; (...); Casado MA

Meeting Abstract. 10.1016/j.jval.2014.08.1659. 2014


Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018


Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome

Cañigral C; (...); Sanz MA

Letter. 10.1007/s00277-013-1970-3. 2014


Editorial: Infectious diseases and hematology: diagnosis and management

Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo

Editorial Material. 10.3389/fmed.2024.1385874. 2024


Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020


EFFECT OF CYP3A5 GENOTYPE ON TACROLIMUS DOSE REQUIREMENT, NEPHROTOXICITY AND ACUTE REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Rojas, L.; (...); Alino, S. F.

Article. 2013


Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

Rojas L; (...); Aliño SF

Article. 10.1038/tpj.2014.38. 2015


Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


EFFECTS OF POLYMORPHIMS OF CYP3A5 AND ABCB1 GENES ON CHRONIC NEPHROPATHY: COHORT STUDY

Rojas, L.; (...); Alino, S. F.

Article. 2013


Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Ferra, Christelle; (...); Baltasar, Patricia

Meeting Abstract. 10.1182/blood-2022-162186. 2022


Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study

Baltasar, Patricia; (...); Ferra, Christelle

Meeting Abstract. 10.1182/blood-2021-147685. 2021


EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY

Martin, EMD; (...); Castera, MJT

Meeting Abstract. 2018

  • Open Access.

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018


Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

Peffault de Latour R; (...); Risitano AM

Article. 10.1056/NEJMoa2109965. 2022


ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL

Risitano, A. M.; (...); de latour, R. Peffault

Meeting Abstract. 2021

  • Open Access.

ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY

Risitano, Antonio Maria; (...); de Latour, Regis Peffault

Meeting Abstract. 2024


Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023


Estudio de utilizacion de boceprevir y telaprevir para el tratamiento de la hepatitis C cronica.

Marrero-Álvarez P; (...); Poveda-Andrés JL

Abstract of Published Item. 10.7399/FH.2014.38.1.1128. 2014


European Perspective on Multiple Myeloma Treatment Strategies in 2014

Ludwig H; (...); Palumbo A

Article. 10.1634/theoncologist.2014-0042. 2014


EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019


Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 10.1016/j.gastrohep.2014.05.004. 2014


Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017


EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY

Paz S; (...); Urcelay J

Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015


Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018


EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019


Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ayyappan, Sabarish; (...); Prince, H. Miles

Meeting Abstract. 10.1182/blood-2023-179818. 2023


Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria

Article. 10.1182/blood.2024024250. 2024


Further psychometric validation of the GAH scale: Responsiveness and effect size

Cruz-Jentoft, AJ; (...); GAH Group

Article. 10.1016/j.jgo.2016.12.008. 2017


Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024


Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024


Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

Bosó V; (...); Aliño SF

Article. 10.1097/FTD.0b013e3182a94e65. 2014


Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.

de la Rubia J; (...); Bonanad, Santiago

Article. 10.1016/j.jgo.2022.10.016. 2022


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017


Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018


Hazardous drugs: new challenges, new opportunities.

Valero García S; (...); Poveda Andrés JL

Article. 10.7399/fh.2016.40.2.10462. 2016


Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022


Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina

Meeting Abstract. 10.1182/blood-2023-180743. 2023


High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022


High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

Puig, J; (...); Castellanos, M

Article. 10.1371/journal.pone.0188238. 2017


Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021


How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022


Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Abrisqueta, Pau; (...); Bosch, Francesc

Article. 10.1016/j.eclinm.2024.102642. 2024


IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP

Rey, Bua Beatriz; (...); Martin, A.

Meeting Abstract. 2020

  • Open Access.

IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.

Vallejo, Carlos; (...); Peman, Javier

Article. 10.3390/jof9060628. 2023


Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.

de la Asuncion Carlos, Solano; (...); Navarro, David

Letter. 10.1111/bjh.18655. 2023


Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Lakhwani S; (...); Hernández MT

Article. 10.1007/s00277-024-06031-0. 2024


Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-166826. 2022


Immunotherapy in multiple myeloma.

Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J

Article. 10.1016/j.medcli.2023.11.019. 2024


Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017


Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017


IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

  • Open Access.

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

  • Open Access.

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017


Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020


Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018


Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017


Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

Ruiz J; (...); Aliño SF

Article. 10.3390/ijms160920168. 2015


Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020


Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Meeting Abstract. 2015


Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019


Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation

Sanz J; (...); Sanz GF

Article. 10.1016/j.bbmt.2013.10.016. 2014


Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020


Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018


Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema

Vallejo, C; (...); Jarque, I

Meeting Abstract. 2020


Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024


Incompatibility of undiluted busulfan injection with a needle-free valve

Cueto-Sola, M; (...); Poveda-Andres, JL

Letter. 10.2146/ajhp140111. 2014


Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018


Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016


Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015


Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019


Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017


Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Meeting Abstract. 2015


Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016


Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019


Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020


Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020


Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024


Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024


Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Rosinol, Laura; (...); Blade Creixenti, Joan

Meeting Abstract. 10.1182/blood-2021-146798. 2021


Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Benboubker L; (...); FIRST Trial Team

Article. 10.1056/NEJMoa1402551. 2014


Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Rosinol, Laura; (...); Blade, Joan

Article. 10.1182/blood.2022019531. 2023


Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

Martin Garcia-Sancho, A.; (...); Caballero, D.

Article. 10.1111/bjh.18989. 2023


Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Mateos MV; (...); San Miguel JF

Article. 10.1056/NEJMoa1300439. 2013


Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab

Marco-Ayala, J; (...); Peris, MLS

Editorial Material. 10.5045/br.2020.2020059. 2020


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021


Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

Rojas LE; (...); Aliño SF

Article. 10.1097/FPC.0b013e3283642fb3. 2013


Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022


Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020


Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

Richardson PG; (...); Bahlis NJ

Article. 10.1056/NEJMoa2303194. 2023


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021


Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018


Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target

Medina, Daniel; (...); Crespo, Marta

Meeting Abstract. 10.1182/blood-2023-185683. 2023


Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021


N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM

Climente Martí M, Poveda Andrés JL, Culebras J

Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021


National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024


Non-traumatic spontaneous abdominal haemorrhage

Ballesta, M.; (...); Lerga, P. Estelles

Article. 10.1016/j.rx.2022.11.003. 2023


Non-traumatic spontaneous abdominal haemorrhage.

Ballesta M; (...); Estellés Lerga P

Article. 10.1016/j.rxeng.2022.11.004. 2023


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022


Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Kim, Won-Seog; (...); Walewski, Jan

Meeting Abstract. 10.1182/blood-2022-158406. 2022


ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023


Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Cabrero M; (...); Caballero D

Article. 10.1038/s41409-023-02171-5. 2024


Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial

Cabrero, M; (...); Caballero, D

Meeting Abstract. 2020


Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023


Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018


OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024


Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

Ibanez, Mariam; (...); Luna I

Article. 10.3390/diagnostics12040953. 2022


Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

San-Miguel, JF; (...); Richardson, PG

Article. 10.1016/S1470-2045(14)70440-1. 2014


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022


Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Gaya, Anna; (...); Vallejo, Carlos

Meeting Abstract. 10.1182/blood-2023-185939. 2023


Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025


Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.2174/1389200218666171101124931. 2018


Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021


Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017


Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017


Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018


PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020


Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016


Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019


Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018


Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters

Herrera Lara S; (...); Morales Suárez-Varela M

Article. 10.1007/s00408-017-0032-3. 2017


PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019


Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Abrisqueta, Pau; (...); Bosch, Francesc

Meeting Abstract. 10.1182/blood-2019-128470. 2019


Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021


Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021


Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

  • Open Access.

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando

Article. 10.1016/j.blre.2023.101112. 2023


Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021


Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Article. 2014


Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Article. 2014


PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

  • Open Access.

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.

Article. 10.1016/j.clml.2022.04.024. 2022


Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1097/DSS.0000000000001046. 2017


Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018


Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.

Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro

Article. 10.1080/09537104.2024.2336104. 2024


Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Abrisqueta, Pau; (...); Villanueva, Miguel

Article. 10.1016/j.clml.2021.07.022. 2021


Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).

Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina

Article. 10.3390/jcm12206422. 2023


Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-167247. 2022


Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Lakhwani S; (...); Hernández MT

Article. 10.3324/haematol.2023.284154. 2024


Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017


Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.

García-Vidal C, Vázquez L, Jarque I

Article. 10.1016/j.riam.2021.03.001. 2021


RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.

Bastos-Oreiro M; (...); López-Guillermo A

Article. 10.1007/s00277-020-03918-6. 2020


Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients

de Latour, RP; (...); Risitano, A

Meeting Abstract. 2020


RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Jarque, Isidro; (...); Peffault, de latour Regis

Meeting Abstract. 2020

  • Open Access.

Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL

Yanez, L; (...); Bosch, F

Meeting Abstract. 2019


Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018


SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020


Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017


Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017


Single Nucleotide Polymorphisms, SNPs, Associated With the Efficacy and Security of Immunosuppressive Treatment in Heart Transplantation

Sanchez-Lazaro, I.; (...); Salvador-Sanz, A.

Article. 10.1016/j.healun.2014.01.392. 2014


SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022


SNPs and taxane toxicity in breast cancer patients

Bosó V; (...); Aliño SF

Article. 10.2217/PGS.14.127. 2014


Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

Cantón R; (...); Solé A

Article. 10.1016/j.arbres.2014.09.021. 2015


Spanish National Registry of Celiac Disease: Incidence and Clinical Presentation

Cilleruelo ML; (...); Ribes-Koninckx C

Article. 10.1097/MPG.0000000000000446. 2014


STUDY OF CHRONIC ANEMIA IN THE ELDERLY

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

  • Open Access.

Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

Pérez-Cebrián M; (...); Llopis-González A

Article. 2015


Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel

Meeting Abstract. 10.1182/blood-2023-179452. 2023


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022


The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022


The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study

Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose

Article. 10.3390/cancers16244189. 2024


The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024


The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018


Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020


Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.

Megías Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.rx.2015.01.008. 2015


Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.

Solves P; (...); Carpio N

Article. 10.1016/j.transci.2019.09.011. 2020


Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizan, L; (...); Polanco, C

Review. 10.2147/PPA.S67253. 2014


Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

Cejalvo, MJ; (...); de la Rubia, J

Article. 10.1007/s00277-021-04529-5. 2021


Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

Bejar, S; (...); Mateu, PN

Meeting Abstract. 2020


Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Bua, BR; (...); Garcia-Sancho, AM

Meeting Abstract. 2021


Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

Garcia, SV; (...); Andres, JLP

Article. 10.1016/j.yrtph.2018.10.002. 2018


Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients

García-Robles AA; (...); Poveda JL

Letter. 10.1016/j.jns.2016.04.048. 2016


USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

  • Open Access.

VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023


Campos de estudio

Compartir